• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Bristol-Myers Squibb (NY:BMY)

    59.59 -1.15 (-1.89%)
    Streaming Delayed Price Updated: 10:49 AM EST, Feb 17, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 3,548,623
    Open 60.85
    Bid (Size) 59.58 (200)
    Ask (Size) 59.60 (900)
    Prev. Close 60.74
    Today's Range 59.57 - 61.30
    52wk Range 42.52 - 63.33
    Shares Outstanding 2,222,113,553
    Dividend Yield 4.23%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma
    From Bristol Myers Squibb
    Via Business Wire
    News headline image
    ASCO GU 2026: Merck and Protara Poised to Disrupt Bladder and Kidney Cancer Standards
    As the oncology community prepares to descend upon San Francisco for the 2026 ASCO Genitourinary (GU) Cancers Symposium from February 26–28, investors and clinicians alike are bracing for data that... 
    Via MarketMinute
    Topics Intellectual Property

    Performance

    YTD
    +11.5%
    +11.5%
    1 Month
    +9.9%
    +9.9%
    3 Month
    +27.3%
    +27.3%
    6 Month
    +23.7%
    +23.7%
    1 Year
    +9.5%
    +9.5%

    More News

    Read More
    News headline image
    The 5 Most Interesting Analyst Questions From Bristol-Myers Squibb’s Q4 Earnings Call
    Via StockStory
    Topics Earnings
    Bristol Myers Squibb Co (NYSE:BMY) Beats Q4 2025 Earnings Estimates and Provides Strong 2026 Outlook ↗
    Via Chartmill
    News headline image
    Incyte (INCY) Deep Dive: Navigating the 2026 Crossroads Following Earnings Miss
    Via Finterra
    Topics Economy Intellectual Property
    News headline image
    Gilead’s Second Act: A 2026 Deep Dive into the Transition from Virology to Oncology Powerhouse
    Via Finterra
    Topics Economy Intellectual Property
    Bristol-Myers Squibb Co (NYSE:BMY) Shows Strong Technical Setup for Potential Breakout ↗
    Via Chartmill
    News headline image
    The Great Pipeline Grab: Life Sciences Deal Volume Skyrockets 82% as Big Pharma Battles the Patent Cliff
    Via MarketMinute
    Topics Artificial Intelligence Economy Intellectual Property
    News headline image
    Roivant Sciences (ROIV): Anatomy of a 15% Surge and the Future of the ‘Vant’ Model
    Via Finterra
    Topics ETFs Economy Initial Public Offering
    News headline image
    BMY Q4 Deep Dive: Growth Portfolio Offsets Legacy Pressure, Pipeline Readouts in Focus
    Via StockStory
    News headline image
    Why Bristol Myers Squibb Stock Topped the Market Today ↗
    Via The Motley Fool
    News headline image
    Bristol Myers (BMY) Q4 2025 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    Bristol-Myers Squibb (NYSE:BMY) Reports Strong Q4 CY2025
    Via StockStory
    News headline image
    Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025
    From Bristol Myers Squibb
    Via Business Wire
    News headline image
    Bristol Myers Squibb Teams Up with Kasey Keller to Share His Lymphoma Journey with Breyanzi
    From Bristol Myers Squibb
    Via Business Wire
    News headline image
    Bristol Myers Q4 Earnings Preview: Profits Under Pressure Even As Wall Street Bets On 2026 Pipeline ↗
    Via Stocktwits
    Topics Artificial Intelligence Intellectual Property Workforce
    News headline image
    Bristol-Myers Squibb Earnings: What To Look For From BMY
    Via StockStory
    News headline image
    Bristol Myers Squibb Introduces "Change the Target. Change What’s Possible.” to Highlight Unmet Needs in Cardiovascular and Thromboembolic Care
    From Bristol Myers Squibb
    Via Business Wire
    News headline image
    The Pharma Reckoning: 2026 Earnings Unveil a New Era of 'TrumpRx' Deals and Looming Patent Cliffs
    Via MarketMinute
    Topics Economy Government Intellectual Property
    News headline image
    The Sound of Silence: Revolution Medicines Plummets 17% as M&A Hopes Evaporate
    Via MarketMinute
    Topics ETFs Government Initial Public Offering
    News headline image
    3 Top Dividend Stocks Yielding More Than 4% to Buy Hand Over Fist This Year ↗
    Via The Motley Fool
    Topics Artificial Intelligence Intellectual Property World Trade
    News headline image
    3 Unpopular Stocks That Concern Us
    Via StockStory
    News headline image
    The Post-Keytruda Pivot: Inside Merck’s Strategic Evolution and the RVMD Landscape
    Via Finterra
    Topics Artificial Intelligence Economy Intellectual Property
    News headline image
    The $6 Billion Disconnect: Why Revolution Medicines (RVMD) Plunged 20% After Merck Talks Collapsed
    Via Finterra
    Topics Economy Initial Public Offering
    News headline image
    2 Under-the-Radar Biotech Stocks Set to Boom in 2026 ↗
    Via The Motley Fool
    Topics ETFs Intellectual Property World Trade

    Frequently Asked Questions

    Is Bristol-Myers Squibb publicly traded?
    Yes, Bristol-Myers Squibb is publicly traded.
    What exchange does Bristol-Myers Squibb trade on?
    Bristol-Myers Squibb trades on the New York Stock Exchange
    What is the ticker symbol for Bristol-Myers Squibb?
    The ticker symbol for Bristol-Myers Squibb is BMY on the New York Stock Exchange
    What is the current price of Bristol-Myers Squibb?
    The current price of Bristol-Myers Squibb is 59.59
    When was Bristol-Myers Squibb last traded?
    The last trade of Bristol-Myers Squibb was at 02/17/26 10:49 AM ET
    What is the market capitalization of Bristol-Myers Squibb?
    The market capitalization of Bristol-Myers Squibb is 132.42B
    How many shares of Bristol-Myers Squibb are outstanding?
    Bristol-Myers Squibb has 132B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.